APP to Begin Shipping Pamidronate Disodium for Injection in 2nd


                         Quarter Of 
                                     2002 


  LOS ANGELES, Nov. 27 /PRNewswire/ -- American Pharmaceutical Partners, 
Inc. (APP) announced today that patent litigation filed against it by Novartis 
Corporation regarding APP's Pamidronate product has been resolved with a 
finding that APP's product does not infringe the Novartis patent on 
Pamidronate.  APP has already received its' tentative approval from the Food 
and Drug Administration (FDA) and plans to begin shipping Pamidronate Disodium 
for Injection, USP, in the first half of 2002.  Pamidronate is the generic 
alternative to Aredia(R), marketed by Novartis Pharmaceuticals, a 
bone-resorption inhibitor indicated for the treatment of hypercalcemia 
associated with malignancy, for Paget's disease, and for osteolytic bone 
metastases of breast cancer and osteolytic lesions of multiple myeloma. 
Aredia had U.S. sales of over $445 million in 2000, according to IMS 
Healthcare.  
(Photo:  http://www.newscom.com/cgi-bin/prnh/20010403/APPLOGO )  
Pamidronate will be bar coded at the individual unit of use level, in an 
attempt to increase patient safety by reducing the frequency of medical 
errors.  
American Pharmaceutical Partners, Inc., is a privately held integrated 
pharmaceutical company with over 800 employees.  APP is one of the leading 
manufacturers and marketers of injectable pharmaceuticals in the United States 
with facilities in Los Angeles, California; Schaumburg, Illinois, Melrose 
Park, Illinois, Grand Island, New York, Bensenville, Illinois and Toronto, 
Canada.  For more information on the Company, visit APP's web site at 
www.appdrugs.com.  
The statements in this release regarding sales of Pamidronate and APP's 
product line may be considered forward-looking statements.  There are a number 
of important factors that could cause actual results to differ materially from 
those suggested or indicated by such forward-looking statements.  These 
include, among others, the date APP launches this product, the market 
acceptance of Pamidronate, the sales and financial performance in future 
periods of this product, the ability of APP to successfully manufacture this 
product in a time-sensitive and cost effective way, the success of our 
competitors to more effectively market and sell comparable or competing 
products, and general economic and regulatory conditions in our industry.  
                  MAKE YOUR OPINION COUNT -  Click Here  
           http://tbutton.prnewswire.com/prn/11690X69244354 
  

SOURCE  American Pharmaceutical Partners, Inc.  
-0-                             11/27/2001  
/CONTACT:  Jeffrey M. Yordon, Chief Operating Officer, +1-847-330-1389, or 
Derek Brown, Chief Operating Officer, +1-310-470-4222, both of American 
Pharmaceutical Partners, Inc./  
/Photo:  http://www.newscom.com/cgi-bin/prnh/20010403/APPLOGO /  
/Web site:  http://www.appdrugs.com /  
CO:  American Pharmaceutical Partners, Inc. 
ST:  California, Illinois 
IN:  HEA MTC 
SU:  PDT LAW  
-0- Nov/27/2001 15:50 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.